Charles Hong

An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy. Read More

The identification of a genetic culprit for hypoplastic left heart syndrome could lead to new treatments for the condition. Read More

Scientists at Vanderbilt University have created a three-dimensional organ-on-a-chip that can mimic the heart’s amazing biomechanical properties in order to study cardiac disease, develop heart drugs. Read More

A team of Vanderbilt investigators developed a new method for rapidly generating heart muscle cells from stem cells. Read More

Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer. Read More

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders. Read More

A polymer hydrogel material developed by Vanderbilt scientists improved the delivery of stem cells for heart repair. Read More

Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer. Read More

Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis. Read More

Vanderbilt investigators used an in vivo screen in zebrafish to identify a potential new anti-cancer drug. Read More

Charles Hong, M.D., Ph.D., and Kevin Niswender, M.D., Ph.D., have been elected to membership in the American Society of Clinical Investigation (ASCI), one of the nation’s most respected medical honor societies. Read More

Compounds developed at Vanderbilt could offer a whole new way to treat atherosclerosis. Read More